Literature DB >> 20069435

Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE.

John B Bossaer1, Philip D Hall, Elizabeth Garrett-Mayer.   

Abstract

PURPOSE: This study seeks to determine the incidence of vancomycin-resistant enterococci (VRE) infection in high-risk neutropenic fever patients colonized with VRE and to determine patient characteristics associated with VRE infection.
METHODS: We conducted a retrospective, single-center, unmatched case-control study. Fifty-three VRE-colonized, high-risk patients with neutropenic fever were identified between January 2006 and February 2009. The two most common diagnoses/conditions included acute myeloid leukemia and hematopoietic stem cell transplantation. Data collected included days of neutropenia, days of fever, demographic data, culture results, and antimicrobial therapy.
RESULTS: Twenty of the 53 patients (38%) with VRE colonization developed a VRE infection. The most common VRE infections were bacteremias (26%). The presence of neutropenia lasting longer than 7 days was associated with the development of VRE infection in this high-risk population colonized with VRE. The timeframe to develop VRE infection varied from 1 day to 2 weeks.
CONCLUSION: For patients colonized with VRE, approximately 38% of high-risk neutropenic patients developed a VRE infection. This is the first study to specifically evaluate the incidence of VRE infections in febrile neutropenic patients colonized with VRE. Future research into the use and efficacy of empiric VRE coverage is needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20069435     DOI: 10.1007/s00520-009-0808-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer.

Authors:  Madonna J Matar; Jeffrey Tarrand; Issam Raad; Kenneth V I Rolston
Journal:  Am J Infect Control       Date:  2006-10       Impact factor: 2.918

3.  Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection.

Authors:  Carlos A DiazGranados; John A Jernigan
Journal:  J Infect Dis       Date:  2005-01-17       Impact factor: 5.226

4.  Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia.

Authors:  P F Smith; M C Birmingham; G A Noskin; A K Meagher; A Forrest; C R Rayner; J J Schentag
Journal:  Ann Oncol       Date:  2003-05       Impact factor: 32.976

5.  A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

Authors:  S M Bhavnani; J A Drake; A Forrest; J A Deinhart; R N Jones; D J Biedenbach; C H Ballow
Journal:  Diagn Microbiol Infect Dis       Date:  2000-03       Impact factor: 2.803

6.  Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.

Authors:  Branimir Jaksic; Giovanni Martinelli; Jaime Perez-Oteyza; Charlotte S Hartman; Linda B Leonard; Kenneth J Tack
Journal:  Clin Infect Dis       Date:  2006-01-25       Impact factor: 9.079

7.  Hematologic effects of linezolid: summary of clinical experience.

Authors:  Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.

Authors:  Almarie Uys; Bernardo L Rapoport; Ronald Anderson
Journal:  Support Care Cancer       Date:  2004-06-09       Impact factor: 3.603

9.  Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE.

Authors:  Chamion N Olivier; Ruth K Blake; Lisa L Steed; Cassandra D Salgado
Journal:  Infect Control Hosp Epidemiol       Date:  2008-05       Impact factor: 3.254

10.  Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant.

Authors:  David M Weinstock; Mary Conlon; Christine Iovino; Tanya Aubrey; Carlota Gudiol; Elyn Riedel; James W Young; Timothy E Kiehn; Gianna Zuccotti
Journal:  Biol Blood Marrow Transplant       Date:  2007-03-23       Impact factor: 5.742

View more
  15 in total

1.  Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies.

Authors:  B J Liss; J J Vehreschild; O A Cornely; M Hallek; G Fätkenheuer; H Wisplinghoff; H Seifert; M J G T Vehreschild
Journal:  Infection       Date:  2012-06-05       Impact factor: 3.553

2.  Oral Bacitracin: A Consideration for Suppression of Intestinal Vancomycin-Resistant Enterococci (VRE) and for VRE Bacteremia From an Apparent Gastrointestinal Tract Source.

Authors:  Truc T Tran; Hannah R Palmer; Marion R Weimar; Cesar A Arias; Gregory M Cook; Barbara E Murray
Journal:  Clin Infect Dis       Date:  2015-02-19       Impact factor: 9.079

Review 3.  The intestinal microbiota and susceptibility to infection in immunocompromised patients.

Authors:  Ying Taur; Eric G Pamer
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

4.  Predictive utility of swab screening for vancomycin-resistant Enterococcus in selection of empiric antibiotics for Enterococcus sterile-site infections: a retrospective cohort study.

Authors:  Ian Brasg; Marion Elligsen; Derek MacFadden; Nick Daneman
Journal:  CMAJ Open       Date:  2017-08-15

5.  Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.

Authors:  Daniela Jabés; Cristina Brunati; GianPaolo Candiani; Simona Riva; Gabriella Romanó; Stefano Donadio
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

6.  Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Jan Vydra; Ryan M Shanley; Ige George; Celalettin Ustun; Angela R Smith; Daniel J Weisdorf; Jo-Anne H Young
Journal:  Clin Infect Dis       Date:  2012-06-12       Impact factor: 9.079

7.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 8.  Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.

Authors:  E Montassier; E Batard; T Gastinne; G Potel; M F de La Cochetière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-25       Impact factor: 3.267

Review 9.  The prevention and management of infections due to multidrug resistant organisms in haematology patients.

Authors:  Jason A Trubiano; Leon J Worth; Karin A Thursky; Monica A Slavin
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 10.  Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).

Authors:  Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann
Journal:  Ann Hematol       Date:  2014-04-29       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.